subject: Brain Tumor - Pipeline Assessment and Market Forecasts to 2017 [print this page] Brain Tumor - Pipeline Assessment and Market Forecasts to 2017
Report Reserve announces inclusion of a new market research report to its premium store.
GlobalData, the industry analysis specialist, has released its new report, "Brain Tumor - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global BRAIN TUMORmarket. The report identifies the key trends shaping and driving the global brain tumor market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain tumor sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Brain Tumor Market is Forecast to Show Positive Growth until 2017
GlobalData estimated the global brain tumor market to be at $914m in 2009, and forecasts it to grow at 11% annually for the next seven years to reach $2.1 billion by 2017. More novel therapies are expected to launch and this factor acts as a major driver for the market. The current market has three products approved for the treatment of brain tumors and there is a high opportunity for the pipeline products to enter into this potential market.
Global Brain Tumor Therapeutics Market Forecast, 20012017
Source: GlobalData, Epidemiology-based Market Forecasting Model, Primary Research Interviews, KOL Interviews
Unmet Need Continues to Challenge the Pipeline Drugs
GlobalData estimates that the prevailing market landscape remains moderate, with few market players, and none of the products seem to be satisfying the unmet needs that exist in the brain tumor market. The current market provides large scope for pipeline drugs that are strong in terms of overall survival, efficacy and safety. As patients become more aware of the latest technological developments, increased efficacy, tolerability and safety profiles will be the key factors that drive the acceptance and market penetration of pipeline products. As the marketed products do not serve the unmet needs, the market continues to offer opportunities for stronger pipeline candidates. However, considering the fact that a majority of the pipeline products are combination and first-in-class, with proven superiority in offering therapeutic performance, the existing market leaders will face significant challenges in maintaining their market shares.
Major Companies Focus on Brain Tumor Drug Development Landscape
GlobalData expects that ANtisense Pharma, EMD Serono, Hoffmann-La Roche Ltd, AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Novartis AG and others will become the leading competitors in the global brain tumor market. These companies, with some of the most technologically advanced products in their pipeline portfolio, are expected to attract the most investor attention in the coming years.
The existing market landscape remains moderate, with only three key products approved. This scenario could change in the near future following multiple product launches by the leading and emerging manufacturers, who are concentrating on novel therapies.
GlobalData analysis shows that products for brain tumor in the developmental pipeline are strong, with 88 molecules in various phases of clinical development, including 66 first-in-class molecules. These first-in-class molecules have distinct advantages over the current marketed products in terms of overall survival, better efficacy and safety profiles, and they may satisfy the unmet need requirement for high efficacy and safety of drugs. If approved, these products will lead to intense competition and the existing market leaders will need to respond quickly in the race to reach blockbuster drug status. For more details, please vist http://www.reportreserve.com/reportdet.php?company=GlobalData&reportid=13189
